Program Fees

Today, the FDA sent out a PDUFA Dear Colleague letter (here) asking firms to verify program fee assessment information that the Agency has relative to applications covered under PDUFA VII.  The letter states that “[u]nder PDUFA VII, a program fee is assessed annually for certain prescription drug products identified in a human drug application approved as of […]